Weight Loss Results
Wegovy Before and After Results
Quick Answer: Clinical trial data shows patients on Wegovy lose an average of 5–7% of body weight within the first three months, around 10% by six months and approximately 15% by 12 months. For a patient starting at 100 kg: ~5–7 kg at 3 months, ~10 kg at 6 months, up to 15 kg within a year. Results vary based on starting weight, adherence, diet and activity.~15%average weight loss at 68 weeks (STEP 1 trial)
~5–7%typical weight loss at 3 months on treatment
4,500+STEP clinical trial participants across all studies
STEP 1 Trial Data
Clinical Trial Results
The STEP 1 trial enrolled 1,961 adults with BMI 30+ (or 27+ with a weight-related comorbidity) for 68 weeks. The semaglutide group achieved average weight loss of 14.9% of body weight, compared with 2.4% in the placebo group.
| Outcome | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Mean weight loss at 68 weeks | 14.9% | 2.4% |
| Weight loss of ≥5% | 86% of participants | 32% of participants |
| Weight loss of ≥10% | 69% of participants | 12% of participants |
| Weight loss of ≥15% | 50% of participants | 5% of participants |
| Weight loss of ≥20% | 32% of participants | 2% of participants |
| Mean absolute weight reduction | ~15.3 kg | ~2.6 kg |
Weight Loss by Starting Weight
Expected Results by Starting Weight
The following examples are based on clinical trial averages. Individual results will vary based on starting weight, metabolic health, diet quality, activity level and adherence to treatment.
Wegovy begins working within the first week, but significant weight loss is a gradual process. The most dramatic results emerge between months 3 and 12 as the dose reaches and sustains 2.4 mg.
| Starting Weight | 5% Loss | 10% Loss | 15% (avg) | 20% Loss |
|---|---|---|---|---|
| 80 kg | 4 kg → 76 kg | 8 kg → 72 kg | 12 kg → 68 kg | 16 kg → 64 kg |
| 100 kg | 5 kg → 95 kg | 10 kg → 90 kg | 15 kg → 85 kg | 20 kg → 80 kg |
| 120 kg | 6 kg → 114 kg | 12 kg → 108 kg | 18 kg → 102 kg | 24 kg → 96 kg |
| 140 kg | 7 kg → 133 kg | 14 kg → 126 kg | 21 kg → 119 kg | 28 kg → 112 kg |
FAQs
Frequently Asked Questions
Clinical trial data from STEP 1 shows average weight loss of 14.9% of body weight over 68 weeks — approximately 15 kg for a 100 kg patient over 16 months. Half of trial participants lost 15% or more; one in three lost 20% or more.
At three months, most Wegovy patients have lost between 5% and 7% of their starting body weight. For someone starting at 100 kg, this means approximately 5–7 kg. Patients who have made dietary improvements alongside treatment tend to see results at the higher end of this range.
Wegovy begins producing biological effects within the first week of injection. Most patients notice reduced appetite within two to three weeks. However, significant weight loss is gradual — the average patient loses 2–4 kg in the first month and around 5–7% by three months.
Yes — a 5% reduction from baseline is a clinically meaningful threshold associated with measurable improvements in blood pressure, blood glucose and cardiovascular risk markers. Achieving 5% loss by month three is consistent with clinical trial averages.
The STEP 4 trial demonstrated that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within 12 months of stopping. This highlights that Wegovy is most effective as a long-term intervention.
Exercise significantly improves body composition outcomes — particularly resistance training, which helps preserve lean muscle mass. It has a modest additional impact on total weight lost but a meaningful impact on the quality of weight loss and longer-term metabolic health.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Wilding JPH et al. STEP 1. N Engl J Med. 2021;384:989–1002. Wadden TA et al. STEP 3. JAMA. 2021. Kushner RF et al. STEP 4. NEJM. 2021. NICE TA875. 2023. Happy Pharmacy (GPhC No. 9012585). This page is for educational purposes only and does not constitute medical advice.